Free Standard AU & NZ Shipping For All Book Orders Over $80!
Register      Login
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
Shopping Cart: ( empty )
You are here: Home > Journals > SH > SH23129
RESEARCH ARTICLE
Contents Vol 21(1)

Acute facial neuralgia related to initiation of emtricitabine/tenofovir for HIV PrEP: a report of two cases in a PrEP demonstration trial

Zhuoheng Yin https://orcid.org/0009-0006-7012-5986 A B # , Rayner Kay Jin Tan B # , Joseph D. Tucker https://orcid.org/0000-0003-2804-1181 B C , Quanmin Li D , Renslow Sherer E , Linghua Li D and Weiming Tang https://orcid.org/0000-0002-9026-707X A B *
+ Author Affiliations
- Author Affiliations

A Dermatology Hospital Southern Medical University, Guangzhou, China.

B University of North Carolina Project-China, Guangzhou, China.

C Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.

D Infectious Disease Center, Guangzhou Eighth People’s Hospital, Guangzhou Medical University, Guangzhou, China.

E Section of Infectious Diseases and Global Health, Department of Medicine, University of Chicago, Chicago, IL, USA.

* Correspondence to: weiming_tang@med.unc.edu
# These authors contributed equally to this paper

Handling Editor: Jason Ong

Sexual Health 21, SH23129 https://doi.org/10.1071/SH23129
Submitted: 24 July 2023  Accepted: 9 January 2024  Published: 29 January 2024

© 2024 The Author(s) (or their employer(s)). Published by CSIRO Publishing

Abstract

Background

Emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) fixed-dose combination (FTC/TDF) is generally well-tolerated, although treatment-related adverse events have been reported.

Methods

We report two cases of persons using FTC/TDF PrEP who had acute neuralgia in a Chinese PrEP demonstration trial.

Results

Neurological symptoms subsided upon treatment discontinuation. Symptoms were reported as similar to one case’s previous experiences with dolutegravir (DTG) + FTC + tenofovir alafenamide (TAF) (for PEP), leading to permanent discontinuation of PrEP.

Conclusion

Acute facial neuralgia appears to be a rare idiosyncratic adverse event to FTC/TDF.

Keywords: adverse effect, discontinuation, facial disturbance, FTC/TDF, MSM, neuralgia, pre-exposure prophylaxis, PrEP.

References

1  Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014; 14(9): 820-9.
| Crossref | Google Scholar | PubMed |

2  Saberi P, Scott HM. On-demand oral pre-exposure prophylaxis with tenofovir/emtricitabine: what every clinician needs to know. J Gen Intern Med 2020; 35: 1285-8.
| Crossref | Google Scholar | PubMed |

3  Centers for Disease Control and Prevention. How effective is PrEP? 2022. Available at https://www.cdc.gov/hiv/basics/prep/prep-effectiveness.html [cited 26 October 2023]

4  World Health Organization. Global state of PrEP; 2022. Available at https://www.who.int/groups/global-prep-network/global-state-of-prep [cited 28 October 2022]

5  Gilead Sciences. Science and medicine; 2023. Available at https://www.gilead.com/science-and-medicine/medicines [cited 20 June 2023]

6  Tang EC, Vittinghoff E, Anderson PL, Cohen SE, Doblecki-Lewis S, Bacon O, et al. Changes in kidney function associated with daily tenofovir disoproxil fumarate/emtricitabine for HIV preexposure prophylaxis use in the United States demonstration project. JAIDS J Acquir Immune Defic Syndr 2018; 77(2): 193-8.
| Crossref | Google Scholar | PubMed |

7  Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363(27): 2587-99.
| Crossref | Google Scholar | PubMed |

8  Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, et al. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2015; 61(4): 572-80.
| Crossref | Google Scholar | PubMed |

9  Sha Y, Li C, Xiong Y, Hazra A, Lio J, Jiang I, et al. Co-creation using crowdsourcing to promote PrEP adherence in China: study protocol for a stepped-wedge randomized controlled trial. BMC Public Health 2022; 22(1): 1697.
| Crossref | Google Scholar | PubMed |

10  Van Slyke L, Scott M. Acute trigeminal neuralgia associated with initiation of emtricitabine/tenofovir for HIV pre-exposure prophylaxis. J Int Assoc Provid AIDS Care JIAPAC 2018; 17: 2325958218760846.
| Crossref | Google Scholar |

11  eHealthMe. Truvada and Trigeminal neuralgia - a phase IV clinical study of FDA data. 2023. Available at https://www.ehealthme.com/ds/truvada/trigeminal-neuralgia/ [accessed 21 January 2024]

12  Owino F, Mandala J, Ambia J, Agot K, Van Damme L. Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenya. Int Med Case Rep J 2013; 6: 91-3.
| Crossref | Google Scholar |

13  Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. J Med Toxicol 2014; 10(1): 26-39.
| Crossref | Google Scholar | PubMed |